https://video.foxnews.com/v/5513640393001/?#sp=show-clips As one can see Dr. Andrew Sloan is involved with DCVAX L for ndGBM for many, many years with results in the near term. Ohio trial locations:[ed States, Ohio University of Cincinnati Cancer Institute Cincinnati, Ohio, United States, 45267 University Hospitals Seidman Cancer Center Cleveland, Ohio, United States, 44106 Cleveland Clinic Foundation Cleveland, Ohio, United States, 44195 Ohio State University Columbus, Ohio, United States, 43210 OhioHealth Columbus, Ohio, United States, 43214https://clinicaltrials.gov/ct2/show/study/NCT00045968?show_locs=Y#locn Not surprisingly, my own findings and others demonstrate that medical institutions and neurosurgeons are BIASED whether Dr. Keith Black of Cedar Sinai doing Maria Menounos; https://investorshub.advfn.com/boards/read_msg.aspx?message_id=132694011 UCSF: Sean Parker's CEO for his The Parker Institute for Cancer Immunotherapy hails from UCSF! which is probably why this LONG key trial has been extended many times: July 28 -- Yonemura v. Powers, "Final Resolution." https://www.pacermonitor.com/public/case/9970453/Yonemura_v_Powers_et_alI Dr. Reardon of Boston's Farber Center has been the sponsor of failed CLDX's GBM trials. ETC ETC I have commented on NVCR's Optune in late 2014: a year BEFORE NVCR's IPO: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=117522379 I introduced Marzan to the company in question who got his fellow compatriots on board. And don't forget the same analyst that wrote up what you and I own did this: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=132735574 Did the above since you'd like me and require substance. Regards. DIFFERENT STROKES FOR DIFFERENT FOLKS